Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab

Qinglin Li¹, Zulei Shao¹, Xiaoling Xu¹+1

• ¹Qinglin Li, MD, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University (Tongde Hospital of Zhejiang Province), Hangzhou, China; Zulei Shao, MM, Postgraduate Training Base Alliance, Wenzhou Medical University, Wenzhou, China;Xiaoling Xu, MD, Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China; and Weimin Mao, MD, >Key Laboratory of Diagnosis and Treatment Technology Research for Thoracic Tumors of Zhejiang, Cancer Hospital of Zhejiang Province, Hangzhou, China.